Morbidly “Healthy” Obese Are Not Metabolically Healthy but Less Metabolically Imbalanced Than Those with Type 2 Diabetes or Dyslipidemia

Obesity Surgery

Volumn 25, Issue 8, 2015, Pages 1380-1391

  Ferrer, Roser ^a   Pardina, Eva ^b   Rossell, Joana ^b   Oller, Laura ^b   Viñas, Anna ^b   Baena Fustegueras, Juan Antonio ^c   Lecube, Albert ^d   Vargas, Víctor ^e   Balibrea, José María ^a   Caubet, Enric ^a   González, Oscar ^a   Vilallonga, Ramón ^a   Fort, Jose Manuel ^a   Peinado Onsurbe, Julia ^b  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Hospital de Arnau de Vilanova   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bariatric surgery; Diabetes; Dyslipidemia; Healthy obese; Inflammation; Obesity

Indexed keywords

ADIPONECTIN; FATTY ACID; GLUCORECEPTOR; GLUCOSE; GLUCOSE RECEPTOR 4; INSULIN; INSULIN RECEPTOR; INTERLEUKIN 6; LEPTIN; LIPID; PHOSPHOLIPID; PLASMINOGEN ACTIVATOR INHIBITOR 1; UNCLASSIFIED DRUG; ADIPOQ PROTEIN, HUMAN; GLUCOSE TRANSPORTER 4; IL6 PROTEIN, HUMAN; SERPINE1 PROTEIN, HUMAN;

ADIPOSE TISSUE; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; CONTROLLED STUDY; DYSLIPIDEMIA; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; INSULIN RESISTANCE; INTRAABDOMINAL FAT; MALE; METABOLIC DISORDER; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; PRIORITY JOURNAL; SATIETY; STOMACH BYPASS; SUBCUTANEOUS FAT; BLOOD; CASE CONTROL STUDY; COMPARATIVE STUDY; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; METABOLISM; MIDDLE AGED; OBESITY, METABOLICALLY BENIGN; OBESITY, MORBID; PATHOLOGY; YOUNG ADULT;

ADIPONECTIN; ADULT; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; GASTRIC BYPASS; GLUCOSE TRANSPORTER TYPE 4; HUMANS; INSULIN; INSULIN RESISTANCE; INTERLEUKIN-6; INTRA-ABDOMINAL FAT; LEPTIN; MALE; MIDDLE AGED; OBESITY, METABOLICALLY BENIGN; OBESITY, MORBID; PLASMINOGEN ACTIVATOR INHIBITOR 1; SUBCUTANEOUS FAT; YOUNG ADULT;

EID: 84938149748     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-014-1528-z     Document Type: Article

References (37)

1. Pataky Z, Bobbioni-Harsch E, Golay A. Open questions about metabolically normal obesity. Int J Obes (Lond). 2010;34 Suppl 2:S18–23.
2. Pataky Z, Bobbioni-Harsch E, Makoundou V, et al. What is the evolution of metabolically normal obesity? Rev Med Suisse. 2011;7(288):692–4.
3. Barbarroja N, Lopez-Pedrera R, Mayas MD, et al. The obese healthy paradox: is inflammation the answer? Biochem J. 2010;430(1):141–9.
4. Pataky Z, Makoundou V, Nilsson P, et al. Metabolic normality in overweight and obese subjects. Which parameters? Which risks? Int J Obes (Lond). 2011;35:1208–15.
5. Pardina E, Baena-Fustegueras JA, Catalan R, et al. Increased expression and activity of hepatic lipase in the liver of morbidly obese adult patients in relation to lipid content. Obes Surg. 2009;19(7):894–904.
6. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. The relationships between IGF-1 and CRP, NO, leptin, and adiponectin during weight loss in the morbidly obese. Obes Surg. 2010;20(5):623–32.
7. NCEP. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.
8. ESH and ESC. Task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25:1105–87.
9. Wildman RP. Healthy obesity. Curr Opin Clin Nutr Metab Care. 2009;12:438–43.
10. Standardization of anthropometric measurements. In: Lohman T, Roche A, Martorel R, eds.Champaign, IL: Human Kinetics Publishers. 1988;39–80.
11. Pardina E, Ferrer R, Baena-Fustegueras JA, et al. Only C-reactive protein, but not TNF-α or IL6, reflects the improvement in inflammation after bariatric surgery. Obes Surg. 2012;22(1):131–9.
12. Marcovina SM, Albers JJ. Apolipoprotein assays: standardization and quality control. Scand J Clin Lab Invest. 1990;50(198):58–65.
13. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28(7):412–9.
14. Aguilar-Salinas CA, Garcia EG, Robles L, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab. 2008;93(10):4075–9.
15. Karelis AD, Faraj M, Bastard JP, et al. The metabolically healthy but obese individual presents a favorable inflammation profile. J Clin Endocrinol Metab. 2005;90(7):4145–50.
16. Meigs JB, Wilson PW, Fox CS, et al. Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J Clin Endocrinol Metab. 2006;91(8):2906–12.
17. Wildman RP, Kaplan R, Manson JE, et al. Body size phenotypes and inflammation in the women’s health initiative observational study. Obesity (Silver Spring). 2011;19(7):1482–91.
18. Phillips CM, Perry IJ. Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab. 2013;98(10):E1610–9.
19. Tchernof A, Despres JP. Pathophysiology of human visceral obesity: an update. Physiol Rev. 2013;93(1):359–404.
20. Brochu M, Tchernof A, Dionne IJ, et al. What are the physical characteristics associated with a normal metabolic profile despite a high level of obesity in postmenopausal women? J Clin Endocrinol Metab. 2001;86(3):1020–5.
21. Shin MJ, Hyun YJ, Kim OY, et al. Weight loss effect on inflammation and LDL oxidation in metabolically healthy but obese (MHO) individuals: low inflammation and LDL oxidation in MHO women. Int J Obes (Lond). 2006;30(10):1529–34.
22. Barbarroja N, Lopez-Pedrera C, Garrido-Sanchez L, et al. Progression from high insulin resistance to type 2 diabetes does not entail additional visceral adipose tissue inflammation. PLoS One. 2012;7:e48155. doi:10.1371/journal.pone.0048155.
23. Elissondo N, Gómez Rosso L, Maidana P, et al. Adiponectina: una adipocitoquina con múltiples funciones protectoras. Acta Bioquim Clin Latinoam. 2008;42(1):17–33.
24. Kadowaki T, Yamauchi T, Kubota N, et al. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006;116(7):1784–92.
25. Degawa-Yamauchi M, Moss KA, Bovenkerk JE, et al. Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res. 2005;13(4):662–9.
26. Matsuzawa Y. Establishment of a concept of visceral fat syndrome and discovery of adiponectin. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(2):131–41.
27. Butner KL, Nickols-Richardson SM, Clark SF, et al. A review of weight loss following Roux-en-Y gastric bypass vs restrictive bariatric surgery: impact on adiponectin and insulin. Obes Surg. 2010;20(5):559–68.
28. Yang WS, Chen MH, Lee WJ, et al. Adiponectin mRNA levels in the abdominal adipose depots of nondiabetic women. Int J Obes Relat Metab Disord. 2003;27:896–900.
29. Altomonte J, Harbaran S, Richter A, et al. Fat depot-specific expression of adiponectin is impaired in Zucker fatty rats. Metab Clin Exp. 2003;52:958–63.
30. Daniele A, Cammarata R, Masullo M, et al. Analysis of adiponectin gene and comparison of its expression in two different pig breeds. Obesity. 2008;16:1869–74.
31. De Rosa A, Monaco ML, Capasso M, et al. Adiponectin oligomers as potential indicators of adipose tissue improvement in obese subjects. Eur J Endocrinol. 2013;169:37–43.
32. Recasens M, Ricart W, Fernandez-Real JM. Obesity and inflammation. Rev Med Univ Navarra. 2004;48(2):49–54.
33. Montague CT, Prins JB, Sanders L, et al. Depot- and sex-specific differences in human leptin mRNA expression: implications for the control of regional fat distribution. Diabetes. 1997;46(3):342–7.
34. Fisher FM, McTernan PG, Valsamakis G, et al. Differences in adiponectin protein expression: effect of fat depots and type 2 diabetic status. Horm Metab Res. 2002;34(11–12):650–4.
35. Rodríguez A, Catalán V, Gómez-Ambrosi J, et al. Visceral and subcutaneous adiposity: are both potential therapeutic targets for tackling the metabolic syndrome? Curr Pharm Des. 2007;13(21):2169–75.
36. Bastard JP, Maachi M, Lagathu C, et al. Recent advances in the relationship between obesity, inflammation, and insulin resistance. Eur Cytokine Netw. 2006;17(1):4–12.
37. Pataky Z, Bobbioni-Harsch E, Golay A. Response to ‘Metabolically normal obesity’ a misnomer? Int J Obes (Lond). 2011;36:165.